Yttrium News and Research

RSS
Yttrium is a metal of the rare earth group of elements. A radioactive form of yttrium may be attached to a monoclonal antibody or other molecule that can locate and bind to cancer cells and be used to diagnose or treat some types of cancer.
FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Eckert & Ziegler receives European Commission's indefinite approval for YTTRIGA

Eckert & Ziegler receives European Commission's indefinite approval for YTTRIGA

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Y-90 microspheres pack a therapeutic punch against late-stage liver cancer

Y-90 microspheres pack a therapeutic punch against late-stage liver cancer

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Study shows radioembolisation with TheraSphere effective for primary liver cancer

Study shows radioembolisation with TheraSphere effective for primary liver cancer

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer

Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Investment report on MIPI

Investment report on MIPI

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009